Search

Your search keyword '"Hagerman, Linda"' showing total 18 results
Start Over Author "Hagerman, Linda"
18 results on '"Hagerman, Linda"'

1. Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Author

Hilton, John, Gelmon, Karen, Bedard, Philippe L., Tu, Dongsheng, Xu, Hong, Tinker, Anna V., Goodwin, Rachel, Laurie, Scott A., Jonker, Derek, Hansen, Aaron R., Veitch, Zachary W., Renouf, Daniel J., Hagerman, Linda, Lui, Hongbo, Chen, Bingshu, Kellar, Deb, Li, Irene, Lee, Sung-Eun, Kono, Takako, Cheng, Brian Y. C., Yap, Damian, Lai, Daniel, Beatty, Sean, Soong, John, Pritchard, Kathleen I., Soria-Bretones, Isabel, Chen, Eric, Feilotter, Harriet, Rushton, Moira, Seymour, Lesley, Aparicio, Samuel, and Cescon, David W.

Published
2022
Full Text
View/download PDF

2. Abstract P3-07-10: CCTG IND.236: A Phase 1b trial of combined CFI-402257 and weekly paclitaxel in patients with HER2-negative (HER2-) advanced breast cancer (aBC)

Author

Bedard, Philippe, primary, Mates, Mihaela, additional, Hilton, John, additional, Levasseur, Nathalie, additional, Awan, Arif, additional, Srikanthan, Amirrtha, additional, Cescon, David W., additional, Gelmon, Karen, additional, Robinson, Andrew, additional, Drummond-Ivars, Nancy, additional, Li, Irene, additional, Rastgou, Laleh, additional, Edwards, Jackie, additional, Hagerman, Linda, additional, Zhang, Siwei, additional, Bray, Mark, additional, Seymour, Lesley, additional, Rushton, Moira, additional, and Gaudreau, Pierre-Olivier, additional

Published
2023
Full Text
View/download PDF

3. Abstract P3-07-18: CCTG IND.239: A phase 2 study of combined CFI-400945 and durvalumab in patients with advanced triple negative breast cancer (aTNBC)

Author

Hilton, John, primary, Cescon, David W., additional, Robinson, Andrew, additional, Dhesy-Thind, Sukhbinder, additional, Taylor, Sara, additional, Awan, Arif, additional, Ng, Terry L., additional, Rushton, Moira, additional, Savard, Marie-France, additional, Muyot, Lindsay, additional, Reeves, Marie Claude, additional, Hagerman, Linda, additional, Lui, Hongbo, additional, Bray, Mark, additional, Tu, Dongsheng, additional, Seymour, Lesley, additional, and Gaudreau, Pierre-Olivier, additional

Published
2023
Full Text
View/download PDF

4. Abstract P3-07-14: A phase II study of CFI-400945 in patients with advanced/metastatic cancer: Canadian Cancer Trials Group (CCTG) IND.237

Author

Cescon, David W., primary, Hilton, John, additional, Bedard, Philippe, additional, Blanchette, Phillip, additional, Pezo, Rossanna C., additional, Bashir, Ayesha, additional, Kumar, Vikaash, additional, Ng, Terry L., additional, Awan, Arif, additional, Lott, Anthony, additional, Raphael, Jacques Antoun, additional, Hagerman, Linda, additional, Bray, Mark, additional, Muyot, Lindsay, additional, Antras, Jesus Fuentes, additional, Seymour, Lesley, additional, Tu, Dongsheng, additional, Gaudreau, Pierre-Olivier, additional, and Rushton, Moira, additional

Published
2023
Full Text
View/download PDF

5. Handling Payment in the Field: Ambulatory practitioners can rein in receivables with a few field-tested strategies from the experts.

Author

Brown, Kimberly S. and Hagerman, Linda

Subjects
BUSINESS skills, BUSINESS success, PAYMENT, ACCOUNTS receivable, BUSINESS consultants
Abstract

The article discusses strategies for ambulatory veterinarians to manage their receivables and collect payment at the time of service. It emphasizes the importance of solo practitioners and group practices establishing a culture of collecting payment early in their careers. The article also highlights the benefits of cost transparency and providing clients with estimates before the appointment. It suggests various tips for ambulatory practitioners, such as accepting different payment methods, using card readers in the field, and being proactive in following up with clients who owe money. The article concludes by emphasizing the importance of managing accounts receivable to create a profitable practice. [Extracted from the article]

Published
2024

7. Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer

Author

Rayson, Daniel, Lupichuk, Sasha, Potvin, Kylea, Dent, Susan, Shenkier, Tamara, Dhesy-Thind, Sukhbinder, Ellard, Susan L., Prady, Catherine, Salim, Muhammad, Farmer, Patricia, Allo, Ghasson, Tsao, Ming-Sound, Allan, Alison, Ludkovski, Olga, Bonomi, Maria, Tu, Dongsheng, Hagerman, Linda, Goodwin, Rachel, Eisenhauer, Elizabeth, and Bradbury, Penelope

Published
2016
Full Text
View/download PDF

8. IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia

Author

Assouline, Sarit, primary, Amrein, Lilian, additional, Aloyz, Raquel, additional, Banerji, Versha, additional, Caplan, Stephen, additional, Owen, Carolyn, additional, Hasegawa, Wanda, additional, Robinson, Sue, additional, Shivakumar, Sudeep, additional, Prica, Anca, additional, Peters, Anthea, additional, Hagerman, Linda, additional, Rodriguez, Laura, additional, Skamene, Tanya, additional, Panasci, Lawrence, additional, Chen, Bingshu E., additional, and Hay, Annette E., additional

Published
2020
Full Text
View/download PDF

9. Abstract PD4-02: Canadian cancer trials group trial IND.231: A phase 1 trial evaluating CX-5461, a novel first-in-class G-quadruplex stabilizer in patients with advanced solid tumors enriched for DNA-repair deficiencies

Author

Hilton, John, primary, Gelmon, Karen, additional, Cescon, David, additional, Tinker, Anna, additional, Jonker, Derek, additional, Goodwin, Rachel, additional, Laurie, Scott, additional, Hansen, Aaron, additional, Aparicio, Samuel, additional, Soong, John, additional, Hagerman, Linda, additional, Lui, Hongbo, additional, Bedard, Philippe, additional, Pritchard, Kathleen, additional, Tu, Dongsheng, additional, and Seymour, Lesley, additional

Published
2020
Full Text
View/download PDF

10. Abstract CT131: A randomized (RCT) phase II study of oncolytic reovirus (pelareorep ) plus standard weekly paclitaxel (P) as therapy for metastatic breast cancer (mBC)

Author

Bernstein, Vanessa, primary, Ellard, Susan, additional, Dent, Susan F., additional, Gelmon, Karen A., additional, Dhesy-Thind, Sukhbinder K., additional, Mates, Mihaela, additional, Salim, Muhammed, additional, Panasci, Lawrence, additional, Song, Xinni, additional, Clemons, Mark, additional, Tu, Dongsheng, additional, Hagerman, Linda J., additional, and Seymour, Lesley, additional

Published
2017
Full Text
View/download PDF

11. A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer

Author

Chia, Stephen K., primary, Ellard, Susan L., additional, Mates, Mihaela, additional, Welch, Stephen, additional, Mihalcioiu, Catalin, additional, Miller, Wilson H., additional, Gelmon, Karen, additional, Lohrisch, Caroline, additional, Kumar, Vikaash, additional, Taylor, Sara, additional, Hagerman, Linda, additional, Goodwin, Rachel, additional, Wang, Tao, additional, Sakashita, Shingo, additional, Tsao, Ming S., additional, Eisenhauer, Elizabeth, additional, and Bradbury, Penelope, additional

Published
2017
Full Text
View/download PDF

12. A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207

Author

Wheatley-Price, Paul, primary, Chu, Quincy, additional, Bonomi, Maria, additional, Seely, Jean, additional, Gupta, Ashish, additional, Goss, Glenwood, additional, Hilton, John, additional, Feld, Ronald, additional, Lee, Christopher W., additional, Goffin, John R, additional, Maksymiuk, Andrew, additional, Murray, Nevin, additional, Hagerman, Linda, additional, and Bradbury, Penelope A., additional

Published
2016
Full Text
View/download PDF

13. Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM).

Author

Petrella, Teresa M., primary, Mihalcioiu, Catalin Liviu Dragos, additional, McWhirter, Elaine, additional, Belanger, Karl, additional, Savage, Kerry J., additional, Song, Xinni, additional, Hamid, Omid, additional, Cheng, Tina, additional, Davis, Mary L., additional, Lee, Christopher W, additional, Spatz, Alan, additional, Monzon, Jose Gerard, additional, Hagerman, Linda, additional, Chen, Bingshu E, additional, and Dancey, Janet, additional

Published
2013
Full Text
View/download PDF

14. A phase Ib study of an anti-HER2 inhibitor, lapatinib, in combination with a c-MET and VEGFR inhibitor, foretinib, in HER2-positive metastatic breast cancer (MBC): Results from NCIC CTG IND.198.

Author

Chia, Stephen K. L., primary, Ellard, Susan, additional, Mates, Mihaela, additional, Welch, Stephen, additional, Mihalcioiu, Catalin Liviu Dragos, additional, Miller, Wilson H., additional, Gelmon, Karen A., additional, Lohrisch, Caroline A., additional, Kumar, Vikaash, additional, Taylor, Sara Kristina, additional, Hagerman, Linda, additional, Eisenhauer, Elizabeth A., additional, and Bradbury, Penelope Ann, additional

Published
2013
Full Text
View/download PDF

15. Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study

Author

Petrella, Teresa M., primary, Tozer, Richard, additional, Belanger, Karl, additional, Savage, Kerry J., additional, Wong, Ralph, additional, Smylie, Michael, additional, Kamel-Reid, Suzanne, additional, Tron, Victor, additional, Chen, Bingshu E., additional, Hunder, Naomi N., additional, Hagerman, Linda, additional, Walsh, Wendy, additional, and Eisenhauer, Elizabeth A., additional

Published
2012
Full Text
View/download PDF

16. Additional file 1: Table S1A. of A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer

Author

Chia, Stephen, Ellard, Susan, Mates, Mihaela, Welch, Stephen, Catalin Mihalcioiu, Miller, Wilson, Gelmon, Karen, Lohrisch, Caroline, Vikaash Kumar, Taylor, Sara, Hagerman, Linda, Goodwin, Rachel, Wang, Tao, Sakashita, Shingo, Tsao, Ming, Eisenhauer, Elizabeth, and Bradbury, Penelope

Subjects
3. Good health
Abstract

Pharmacokinetics of lapatinib. Table S1B. Pharmacokinetics of foretinib. (DOCX 558 kb)

17. Additional file 1: Table S1A. of A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer

Author

Chia, Stephen, Ellard, Susan, Mates, Mihaela, Welch, Stephen, Catalin Mihalcioiu, Miller, Wilson, Gelmon, Karen, Lohrisch, Caroline, Vikaash Kumar, Taylor, Sara, Hagerman, Linda, Goodwin, Rachel, Wang, Tao, Sakashita, Shingo, Tsao, Ming, Eisenhauer, Elizabeth, and Bradbury, Penelope

Subjects
3. Good health
Abstract

Pharmacokinetics of lapatinib. Table S1B. Pharmacokinetics of foretinib. (DOCX 558 kb)

18. A Phase II Clinical Trial of the Pan PI3K Inhibitor, Buparlisib, for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia: Canadian Cancer Trials Group IND.216

Author

Assouline, Sarit, Amrein, Lilian, Banerji, Versha, Caplan, Stephen, Owen, Carolyn Jane, Hasegawa, Wanda, Robinson, Sue, Shavikumar, Sudeep, Prica, Anca, Peters, Anthea, Hagerman, Linda, Rodriguez, Laura, Skamene, Tanya, Panasci, Lawrence, Chen, Bingshu E., and Hay, Annette E

Abstract

Introduction: Inhibition of the phospho-inositol 3 kinase (PI3K) delta isoform is effective in the treatment of relapsed and refractory chronic lymphocytic leukemia (CLL) (Pongas G, et al. Semin Oncol2016; 43: 647). The efficacy of this class of drugs is limited by the potency of the inhibitor and its toxicity profile. Buparlisib is an orally available pan-Class I PI3K inhibitor which has greater potency than idelalisib in vitro. Low P70S6k and raptor levels, both of which are downstream regulators of the PI3K/mTOR pathway, correlate with sensitivity to PI3K inhibitor activity in CLL lymphocytes in vitro(Amrein L, et al. Int J Cancer2013; 133: 247-52). The recommended phase II dose of buparlisib is 100 mg daily po and the main toxicities in Phase I were hyperglycemia, hypertension and mood disturbance (Bendell JC, et al. J Clin Oncol.2012;30:282-90). We conducted a single arm phase II trial of buparlisib in patients with relapsed and refractory CLL (NCT02340780) and attempted to correlate response with P70S6k and raptor levels.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results